Hemostatic Imbalance in Thalassemia: From Molecular Mechanisms to Clinical Manifestations
DOI:
https://doi.org/10.67224/ioasdjmps.2026.v03i03.004Keywords:
Thalassemia, Hemostatic imbalance, Coagulation disorders, Hypercoagulability, Molecular mechanismsAbstract
Thalassemia is a hereditary hemoglobinopathy characterized by defective globin chain synthesis, leading to chronic anemia and systemic complications. Among these, hemostatic imbalance has gained increasing attention due to its contribution to significant morbidity and mortality. This review explores the complex molecular mechanisms underpinning coagulation disturbances in thalassemia, including chronic hemolysis-induced endothelial dysfunction, platelet activation, microparticle generation, and coagulation factor alterations. These pathophysiological changes foster a prothrombotic state while occasionally predisposing to bleeding complications. Clinically, patients with thalassemia exhibit a broad spectrum of hemostatic manifestations ranging from thromboembolic events such as deep vein thrombosis and stroke to bleeding tendencies associated with platelet dysfunction and coagulopathy. Diagnostic evaluation is complicated by overlapping clinical features and the limitations of routine coagulation assays, necessitating more advanced testing modalities to accurately assess coagulation status and guide management. The impact of factors such as splenectomy, iron overload, and oxidative stress on hemostasis further complicates clinical care. Effective management of hemostatic imbalance in thalassemia requires a multidisciplinary approach that balances thrombotic and bleeding risks. Current strategies include anticoagulation, iron chelation, and careful monitoring of coagulation parameters. Advances in molecular diagnostics and emerging targeted therapies offer promising avenues for personalized care. This review underscores the importance of understanding hemostatic alterations in thalassemia to improve clinical outcomes and highlights areas for future research.
References
1. Sadiq, I. Z., Abubakar, F. S., Usman, H. S., Abdullahi, A. D., Ibrahim, B., Kastayal, B. S., ... & Hassan, H. A. (2024). Thalassemia: Pathophysiology, diagnosis, and advances in treatment. Thalassemia Reports, 14(4), 81-102. https://doi.org/10.3390/thalassrep14040010
2. Ali, S., Mumtaz, S., Shakir, H. A., Khan, M., Tahir, H. M., Mumtaz, S., ... & Khan, M. A. (2021). Current status of beta‐thalassemia and its treatment strategies. Molecular genetics & genomic medicine, 9(12), e1788. doi: 10.1002/mgg3.1788.
3. Tesio, N., & Bauer, D. E. (2023). Molecular basis and genetic modifiers of thalassemia. Hematology/oncology clinics of North America, 37(2), 273-299. doi: 10.1016/j.hoc.2022.12.001.
4. Obeagu, E. I. (2025). Thalassemia in Sub-Saharan Africa: epidemiology, diagnosis, and management–a narrative review. Annals of Medicine and Surgery, 87(6), 3523-3536. doi: 10.1097/MS9.0000000000003270.
5. Obeagu, E. I. (2025). Climate change and red blood cell disorders: A review of risks and adaptations for pregnant women and children. Medicine, 104(40), e45129. doi: 10.1097/MD.0000000000045129.
6. Sadiq, I. Z., Abubakar, F. S., Usman, H. S., Abdullahi, A. D., Ibrahim, B., Kastayal, B. S., ... & Hassan, H. A. (2024). Thalassemia: Pathophysiology, diagnosis, and advances in treatment. Thalassemia Reports, 14(4), 81-102. https://doi.org/10.3390/thalassrep14040010
7. Huang, Y., Lei, Y., Liu, R., Liu, J., Yang, G., Xiang, Z., ... & Lai, Y. (2019). Imbalance of erythropoiesis and iron metabolism in patients with thalassemia. International Journal of Medical Sciences, 16(2), 302-310. doi: 10.7150/ijms.27829.
8. Morris, C. R., Kuypers, F. A., Kato, G. J., Lavrisha, L., Larkin, S., Singer, T., & Vichinsky, E. P. (2005). Hemolysis‐associated pulmonary hypertension in thalassemia. Annals of the New York Academy of Sciences, 1054(1), 481-485. doi: 10.1196/annals.1345.058.
9. Frimat, M., Boudhabhay, I., & Roumenina, L. T. (2019). Hemolysis derived products toxicity and endothelium: model of the second hit. Toxins, 11(11), 660.. https://doi.org/10.3390/toxins11110660
10. Pattanapanyasat, K., Gonwong, S., Chaichompoo, P., Noulsri, E., Lerdwana, S., Sukapirom, K., ... & Fucharoen, S. (2007). Activated platelet‐derived microparticles in thalassaemia. British journal of haematology, 136(3), 462-471. doi: 10.1111/j.1365-2141.2006.06449. x.
11. Cappellini, M. D., Musallam, K. M., Marcon, A., & Taher, A. T. (2009). Coagulopathy in beta-thalassemia: current understanding and future perspectives. Mediterranean journal of hematology and infectious diseases, 1(1), e2009029. doi: 10.4084/MJHID.2009.029.
12. Al-Sanabra, O. M., Abbas, M. A., Hazà, W. J., Hazàa, A. A., & Al Tibi, A. K. (2025). Coagulation and Fibrinolysis Dysregulation in β-Thalassemia Major: Potential Impact of Splenectomy and Medications on Thrombotic Risk. Clinical and Applied Thrombosis/Hemostasis, 31, 10760296251359291. doi: 10.1177/10760296251359291.
13. Pablo-Moreno, J. A. D., Serrano, L. J., Revuelta, L., Sanchez, M. J., & Liras, A. (2022). The vascular endothelium and coagulation: homeostasis, disease, and treatment, with a focus on the von Willebrand factor and factors VIII and V. International journal of molecular sciences, 23(15), 8283. https://doi.org/10.3390/ijms23158283
14. Crary, S. E., & Buchanan, G. R. (2009). Vascular complications after splenectomy for hematologic disorders. Blood, The Journal of the American Society of Hematology, 114(14), 2861-2868. doi: 10.1182/blood-2009-04-210112.
15. Basnet, A., Acharya, B., Shrestha, M., & Thapa, S. (2025). Deep Vein Thrombosis in a Patient With Thalassemia Minor: A Case Report. Clinical Case Reports, 13(11), e71497. doi: 10.1002/ccr3.71497.
16. Eldor, A., & Rachmilewitz, E. A. (2002). The hypercoagulable state in thalassemia. Blood, The Journal of the American Society of Hematology, 99(1), 36-43. doi: 10.1182/blood. v99.1.36.
17. Rabie, M. A. F., El Benhawy, S. A., Masoud, I. M., Arab, A. R., & Saleh, S. A. (2024). Impact of met-haemoglobin and oxidative stress on endothelial function in patients with transfusion dependent β-thalassemia. Scientific Reports, 14(1), 25328. doi: 10.1038/s41598-024-74930-3.
18. Chuljerm, H., Maneekesorn, S., Thorup, G., Nantakool, S., Charoenkwan, P., & Rerkasem, K. (2025). The relevance of endothelial dysfunction biomarkers in thalassemia patients and healthy individuals: a systematic review and meta-analysis. International Journal of Molecular Sciences, 26(8), 3842. https://doi.org/10.3390/ijms26083842
19. Koupenova, M., Clancy, L., Corkrey, H. A., & Freedman, J. E. (2018). Circulating platelets as mediators of immunity, inflammation, and thrombosis. Circulation research, 122(2), 337-351. doi: 10.1161/CIRCRESAHA.117.310795.
20. Badulescu, O. V., Ciocoiu, M., Vladeanu, M. C., Huzum, B., Plesoianu, C. E., Iliescu-Halitchi, D., ... & Bojan, I. B. (2025). The role of platelet dysfunctions in the pathogenesis of the hemostatic-coagulant system imbalances. International Journal of Molecular Sciences, 26(6), 2756. doi: 10.3390/ijms26062756.
21. Ahmadi, A., Hosseini, S., Dorgalaleh, A., Hassani, S., Tabibian, S., Tavasoli, B., ... & Shams, M. (2024). Natural anticoagulant protein levels in patients with beta-thalassemia major: A case-control study. Journal of hematology, 13(1-2), 23. doi: 10.14740/jh1217.
22. Miceli, G., Ciaccio, A. M., & Tuttolomondo, A. (2025). From circulating biomarkers to polymorphic variants: A narrative review of challenges in thrombophilia evaluation. Journal of Clinical Medicine, 14(10), 3448. https://doi.org/10.3390/jcm14103448
23. Kuijpers, M. J., Heemskerk, J. W., & Jurk, K. (2022). Molecular mechanisms of hemostasis, thrombosis and thrombo-inflammation. International Journal of molecular sciences, 23(10), 5825. https://doi.org/10.3390/ijms23105825
24. Succar, J., Musallam, K. M., & Taher, A. T. (2011). Thalassemia and venous thromboembolism. Mediterranean journal of hematology and infectious diseases, 3(1), e2011025. doi: 10.4084/MJHID.2011.025.
25. Saliba, A. N., Atoui, A., Labban, M., Hamade, H., Bou-Fakhredin, R., Mufarrij, A., & Taher, A. T. (2020). Thalassemia in the emergency department: special considerations for a rare disease. Annals of Hematology, 99(9), 1967-1977. doi: 10.1007/s00277-020-04164-6.
26. Tripodi, A., Cappellini, M. D., Chantarangkul, V., Padovan, L., Fasulo, M. R., Marcon, A., & Mannucci, P. M. (2009). Hypercoagulability in splenectomized thalassemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in platelet-poor plasma. haematologica, 94(11), 1520-7. doi: 10.3324/haematol.2009.010546.
27. Singh, S., Yadav, G., Kushwaha, R., Jain, M., Ali, W., Verma, N., ... & Singh, U. S. (2021). Bleeding versus thrombotic tendency in young children with beta-thalassemia major. Cureus, 13(12) e20192. doi: 10.7759/cureus.20192.
28. van den Boom, B. P., & Lisman, T. (2022). Pathophysiology and management of bleeding and thrombosis in patients with liver disease. International journal of laboratory hematology, 44, 79-88. doi: 10.1111/ijlh.13856.
29. Obeagu, E. I. (2025). Pediatric thrombosis: Risk factors, diagnosis, and prevention strategies. Medicine, 104(29), e43370. doi: 10.1097/MD.0000000000043370.
30. O’Brien, S. H., & Zia, A. (2022). Hemostatic and thrombotic disorders in the pediatric patient. Blood, The Journal of the American Society of Hematology, 140(6), 533-541. doi: 10.1182/blood.2020006477.
31. Schulze, K. M., Weber, R. E., Horn, A. G., Colburn, T. D., Ade, C. J., Poole, D. C., & Musch, T. I. (2022). Effects of pulmonary hypertension on microcirculatory hemodynamics in rat skeletal muscle. Microvascular research, 141, 104334. doi: 10.1016/j.mvr.2022.104334.
32. Mathew, R., Huang, J., Wu, J. M., Fallon, J. T., & Gewitz, M. H. (2016). Hematological disorders and pulmonary hypertension. World Journal of Cardiology, 8(12), 703-718. doi: 10.4330/wjc.v8.i12.703.
33. Favaloro, E. J., & Pasalic, L. (2024). Innovative diagnostic solutions in hemostasis. Diagnostics, 14(22), 2521. https://doi.org/10.3390/diagnostics14222521
34. Gong, J. M., Shen, Y., & He, Y. X. (2016). Reference intervals of routine coagulation assays during the pregnancy and puerperium period. Journal of clinical laboratory analysis, 30(6), 912-917. doi: 10.1002/jcla.21956.
35. Korpallová, B., Samoš, M., Bolek, T., Škorňová, I., Kovář, F., Kubisz, P., ... & Mokáň, M. (2018). Role of thromboelastography and rotational thromboelastometry in the management of cardiovascular diseases. Clinical and Applied Thrombosis/Hemostasis, 24(8), 1199-1207. doi: 10.1177/1076029618790092.
36. Rajpal, S., Ahluwalia, J., Kumar, N., Malhotra, P., & Uppal, V. (2019). Elevated von Willebrand factor antigen levels are an independent risk factor for venous thromboembolism: first report from North India. Indian Journal of Hematology and Blood Transfusion, 35(3), 489-495. doi: 10.1007/s12288-019-01092-y.
37. Choi, J. L., Li, S., & Han, J. Y. (2014). Platelet function tests: a review of progresses in clinical application. BioMed research international, 2014(1), 456569. doi: 10.1155/2014/456569.
38. Hvas, C. L., & Larsen, J. B. (2023). The fibrinolytic system and its measurement: history, current uses and future directions for diagnosis and treatment. International Journal of Molecular Sciences, 24(18), 14179. doi: 10.3390/ijms241814179.
39. Balestra, D., & Branchini, A. (2019). Molecular mechanisms and determinants of innovative correction approaches in coagulation factor deficiencies. International journal of molecular sciences, 20(12), 3036. https://doi.org/10.3390/ijms20123036
40. Kholmukhamedov, A., Subbotin, D., Gorin, A., & Ilyassov, R. (2025). Anticoagulation management: current landscape and future trends. Journal of clinical medicine, 14(5), 1647. https://doi.org/10.3390/jcm14051647
41. Kalamara, T. V., Dodos, K., & Vlachaki, E. (2023). Splenectomy is significantly associated with thrombosis but not with pulmonary hypertension in patients with transfusion-dependent thalassemia: a meta-analysis of observational studies. Frontiers in Medicine, 10, 1259785. doi: 10.3389/fmed.2023.1259785.
42. Lee, R. H., Kasthuri, R. S., & Bergmeier, W. (2020). Platelet transfusion for patients with platelet dysfunction: effectiveness, mechanisms, and unanswered questions. Current opinion in hematology, 27(6), 378-385. doi: 10.1097/MOH.0000000000000608.
43. Yamada, S., & Asakura, H. (2024). How we interpret thrombosis with thrombocytopenia syndrome?. International Journal of Molecular Sciences, 25(9), 4956. https://doi.org/10.3390/ijms25094956
44. Bayanzay, K., & Alzoebie, L. (2016). Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectives. Journal of blood medicine, 159-169. doi: 10.2147/JBM.S61540.
45. Chaudhary, P. K., Kim, S., & Kim, S. (2022). An insight into recent advances on platelet function in health and disease. International Journal of Molecular Sciences, 23(11), 6022. doi: 10.3390/ijms23116022.
46. Faranoush, M., Faranoush, P., Heydari, I., Foroughi‐Gilvaee, M. R., Azarkeivan, A., Parsai Kia, A., ... & Rohani, F. (2023). Complications in patients with transfusion dependent thalassemia: A descriptive cross‐sectional study. Health Science Reports, 6(10), e1624. doi: 10.1002/hsr2.1624.
47. Iolascon, A., Andolfo, I., Barcellini, W., Corcione, F., Garçon, L., De Franceschi, L., ... & Tamary, H. (2017). Recommendations regarding splenectomy in hereditary hemolytic anemias. haematologica, 102(8), 1304. doi: 10.3324/haematol.2016.161166.
48. Tesio, N., & Bauer, D. E. (2023). Molecular basis and genetic modifiers of thalassemia. Hematology/oncology clinics of North America, 37(2), 273-299. doi: 10.1016/j.hoc.2022.12.001.
49. Burke, W., Parens, E., Chung, W. K., Berger, S. M., & Appelbaum, P. S. (2022). The challenge of genetic variants of uncertain clinical significance: a narrative review. Annals of internal medicine, 175(7), 994-1000. doi: 10.7326/M21-4109.
50. Hershkop, M., Rafiee, B., & Friedman, M. T. (2025). The Application of Viscoelastic Testing in Patient Blood Management. Encyclopedia, 5(3), 110. https://doi.org/10.3390/encyclopedia5030110
51. Assar, M., Nilius, H., Kearn, N., Hopman, W., Nagler, M., & Othman, M. (2025). Thromboelastometry (ROTEM) Assessing Hypercoagulability in Patients Referred for Thrombophilia Screening. International Journal of Laboratory Hematology, 47(3), 520-528. doi: 10.1111/ijlh.14443.
52. Lee, W. J., Mohd Tahir, N. A., Chun, G. Y., & Li, S. C. (2024). The impact of chelation compliance in health outcome and health related quality of life in thalassaemia patients: a systematic review. Health and Quality of Life Outcomes, 22(1), 14. doi: 10.1186/s12955-023-02221-y.
53. Shen, C. L., & Wu, Y. F. (2022). Flow cytometry for evaluating platelet immunophenotyping and function in patients with thrombocytopenia. Tzu Chi Medical Journal, 34(4), 381-387. doi: 10.4103/tcmj.tcmj_117_22.
54. Wegrzyn, G., Walborn, A., Rondina, M., Fareed, J., & Hoppensteadt, D. (2021). Biomarkers of platelet activation and their prognostic value in patients with sepsis-associated disseminated intravascular coagulopathy. Clinical and applied thrombosis/hemostasis, 27, 1076029620943300. doi: 10.1177/1076029620943300.
55. Baidildinova, G., Nagy, M., Jurk, K., Wild, P. S., Ten Cate, H., & Van der Meijden, P. E. (2021). Soluble platelet release factors as biomarkers for cardiovascular disease. Frontiers in cardiovascular medicine, 8, 684920. doi: 10.3389/fcvm.2021.684920.
56. Favaloro, E. J., & Lippi, G. (2017). Translational aspects of developmental hemostasis: infants and children are not miniature adults and even adults may be different. Annals of Translational Medicine, 5(10), 212. doi: 10.21037/atm.2017.04.18.
57. Pichler, E., & Pichler, L. (2008). The neonatal coagulation system and the vitamin K deficiency bleeding–a mini review. Wiener Medizinische Wochenschrift, 158(13), 385-395. doi: 10.1007/s10354-008-0538-7.
58. Liao, H., Zhang, F., Chen, F., Li, Y., Sun, Y., Sloboda, D. D., ... & Hu, T. (2025). Application of artificial intelligence in laboratory hematology: Advances, challenges, and prospects. Acta Pharmaceutica Sinica B. 15(11):5702-5733. doi: 10.1016/j.apsb.2025.05.036.
59. Obeagu, E. I., Ezeanya, C. U., Ogenyi, F. C., & Ifu, D. D. (2025). Big data analytics and machine learning in hematology: Transformative insights, applications and challenges. Medicine, 104(10), e41766. doi: 10.1097/MD.0000000000041766.
60. Obeagu, E. I., & Ogenyi, F. C. (2025). Artificial intelligence in African malaria control programs: opportunities and risks. Annals of Medicine and Surgery, 87(12), 8664-8670. doi: 10.1097/MS9.0000000000004259.
61. Obeagu, E. I. (2025). Revolutionizing hematological disorder diagnosis: unraveling the role of artificial intelligence. Annals of Medicine and Surgery, 87(6), 3445-3457. doi: 10.1097/MS9.0000000000003227.
62. Wood, J. C. (2023). Cardiac complications in thalassemia throughout the lifespan: Victories and challenges. Annals of the New York Academy of Sciences, 1530(1), 64-73. doi: 10.1111/nyas.15078.
63. Taberna, M., Gil Moncayo, F., Jané-Salas, E., Antonio, M., Arribas, L., Vilajosana, E., ... & Mesía, R. (2020). The multidisciplinary team (MDT) approach and quality of care. Frontiers in oncology, 10, 85. doi: 10.3389/fonc.2020.00085.
64. Ezeamii, V. C., Okobi, O. E., Wambai-Sani, H., Perera, G. S., Zaynieva, S., Okonkwo, C. C., ... & Obiefuna, N. G. (2024). Revolutionizing healthcare: how telemedicine is improving patient outcomes and expanding access to care. Cureus, 16(7) e63881. doi: 10.7759/cureus.63881.
65. Nasiri, A., Alshammari, M., Alqahtani, R., Alshaer, O., Alsolamy, E., Alghethber, H., & Alkharras, R. (2025). Next-Generation Anticoagulants: Precision Strategies for Patient-Centered Thromboprophylaxis. Journal of Personalized Medicine, 15(10), 490. doi: 10.3390/jpm15100490.
66. Das, D., Shruthi, N. R., Banerjee, A., Jothimani, G., Duttaroy, A. K., & Pathak, S. (2023). Endothelial dysfunction, platelet hyperactivity, hypertension, and the metabolic syndrome: molecular insights and combating strategies. Frontiers in nutrition, 10, 1221438. doi: 10.3389/fnut.2023.1221438.
67. Cosenza, L. C., Gasparello, J., Romanini, N., Zurlo, M., Zuccato, C., Gambari, R., & Finotti, A. (2021). Efficient CRISPR-Cas9-based genome editing of β-globin gene on erythroid cells from homozygous β039-thalassemia patients. Molecular Therapy Methods & Clinical Development, 21, 507-523. doi: 10.1016/j.omtm.2021.03.025.
68. Su, J., Yang, L., Sun, Z., & Zhan, X. (2024). Personalized drug therapy: innovative concept guided with proteoformics. Molecular & Cellular Proteomics, 23(3):100737. doi: 10.1016/j.mcpro.2024.100737.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Emmanuel Ifeanyi Obeagu (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The IOASD Journal of Medical and Pharmaceutical Sciences publishes all articles under the Creative Commons Attribution–NonCommercial 4.0 International (CC BY-NC 4.0) License. Under this license, readers are free to copy, distribute, share, adapt, and reproduce the published work in any medium or format for non-commercial purposes, provided that appropriate credit is given to the original author(s) and the source.
